Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Sep 10 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 10, 2024, titled "Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases